EORTC survey looks at common practices in melanoma surgery

NewsGuard 100/100 Score

The European Organisation for Research and Treatment of Cancer (EORTC) has conducted an international survey of 75 melanoma centres on their behaviours and practices. The survey, which was conducted between 2003-2005, looked at common surgical practices in melanoma surgery (resection margins, sentinel node biopsy and lymph node dissection), as well as surgical management of distant metastases and the use of Isolate Limb Perfusion. The results of the survey have been published in ecancermedicalscience, the journal of the European Institute of Oncology and the OECI.

It is known that melanoma surgical guidelines vary between nations and EORTC conducted the survey to identify the effect these differences had on surgical practice. Its goal was to compare behaviours and beliefs among EORTC members and non-members. The authors also compared the survey results with relevant clinical trials and studies to identify common practices in melanoma treatments.

In the future, the EORTC Melanoma Group hopes to develop an updated version, taking into account newer treatments. The results can then be used to determine the differences developed in practice and behaviour over the ten year period.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough study reveals melanoma's resistance tactics to targeted therapy